Hotchkis & Wiley Capital Management LLC Raises Holdings in Zynex, Inc. (NASDAQ:ZYXI)

Hotchkis & Wiley Capital Management LLC raised its holdings in shares of Zynex, Inc. (NASDAQ:ZYXI - Free Report) by 24.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 746,380 shares of the company's stock after acquiring an additional 147,770 shares during the quarter. Hotchkis & Wiley Capital Management LLC owned approximately 2.34% of Zynex worth $6,090,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently added to or reduced their stakes in the company. Gladius Capital Management LP boosted its stake in Zynex by 53.4% during the 3rd quarter. Gladius Capital Management LP now owns 5,002 shares of the company's stock worth $41,000 after purchasing an additional 1,742 shares during the last quarter. Investment Partners Asset Management Inc. purchased a new stake in Zynex in the 3rd quarter valued at approximately $96,000. Hsbc Holdings PLC purchased a new stake in Zynex in the 2nd quarter valued at about $113,000. Quest Partners LLC boosted its position in Zynex by 646.7% during the 2nd quarter. Quest Partners LLC now owns 12,926 shares of the company's stock worth $120,000 after purchasing an additional 11,195 shares during the period. Finally, Principal Financial Group Inc. raised its holdings in Zynex by 10.4% in the second quarter. Principal Financial Group Inc. now owns 19,525 shares of the company's stock valued at $182,000 after acquiring an additional 1,846 shares in the last quarter. 29.68% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms recently commented on ZYXI. Royal Bank of Canada lowered their price objective on shares of Zynex from $12.00 to $11.00 and set an "outperform" rating on the stock in a research note on Tuesday, October 8th. HC Wainwright reaffirmed a "buy" rating and issued a $17.00 price objective on shares of Zynex in a research note on Friday.

Zynex Trading Up 2.4 %

Shares of Zynex stock traded up $0.19 during trading on Friday, reaching $8.13. 53,349 shares of the company were exchanged, compared to its average volume of 162,753. The business has a 50-day moving average price of $8.25 and a 200-day moving average price of $8.61. The company has a quick ratio of 3.15, a current ratio of 3.94 and a debt-to-equity ratio of 1.66. The firm has a market capitalization of $258.94 million, a price-to-earnings ratio of 52.93 and a beta of 0.49. Zynex, Inc. has a twelve month low of $7.15 and a twelve month high of $13.77.

Zynex (NASDAQ:ZYXI - Get Free Report) last posted its earnings results on Thursday, October 24th. The company reported $0.07 earnings per share for the quarter, topping analysts' consensus estimates of $0.06 by $0.01. Zynex had a return on equity of 13.05% and a net margin of 2.49%. The company had revenue of $49.97 million during the quarter, compared to the consensus estimate of $50.83 million. During the same quarter last year, the firm earned $0.10 earnings per share. The company's revenue was up .1% on a year-over-year basis. Sell-side analysts anticipate that Zynex, Inc. will post 0.2 EPS for the current fiscal year.

Insider Activity at Zynex

In other Zynex news, CFO Daniel J. Moorhead sold 10,000 shares of the stock in a transaction on Friday, November 1st. The stock was sold at an average price of $8.59, for a total transaction of $85,900.00. Following the sale, the chief financial officer now owns 44,878 shares in the company, valued at $385,502.02. This represents a 18.22 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In the last quarter, insiders have sold 34,000 shares of company stock valued at $289,240. 52.13% of the stock is owned by corporate insiders.

Zynex Profile

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.